» Articles » PMID: 32503644

Immunopathology in Schistosomiasis is Regulated by TLR2,4- and IFN-γ-activated MSC Through Modulating Th1/Th2 Responses

Overview
Publisher Biomed Central
Date 2020 Jun 7
PMID 32503644
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: A marked egg-induced CD4 T cell programmed inflammation and subsequent hepatic fibrosis characterize the pathogenesis of schistosomiasis. Mesenchymal stem cell (MSC) has been extensively studied for the treatment of schistosomiasis. However, the mechanism by which MSCs modulate the pathogenesis of schistosomiasis has not been clarified. Furthermore, the local inflammatory milieu may greatly influence the immunoregulatory properties of MSCs, and our early experiments demonstrated that Toll-like receptor (TLR)2/TLR4 agonist effected immune modulation of MSC. Here, we further investigated their modulation on the pathogenesis of schistosomiasis.

Methods: Adult BALB/c male mice were percutaneously infected with 16 ± 2 pairs S. japonicum cercariae and received intravenously pretreated MSC at 1 week and 3 weeks post-infection, respectively. At 8 weeks post-infection, effects of MSC on liver histology were shown by hematoxylin and eosin (H&E) staining and Masson staining and quantitatively compared by the hepatic hydroxyproline content; α-smooth muscle actin (α-SMA), collagen type I(Col-1), transforming growth factor β (TGF-β), and tumor necrosis factor-α (TNF-α) gene expression in the liver were assessed by semi-quantitative polymerase chain reaction (PCR); the Th1/Th2 dominance among different groups was compared by analyzing CD4 interferon-γ (IFN-γ)+ and CD4+interleukin-4 (IL-4)+T cells in the liver by flow cytometry and serum level of IFN-γ and IL-5 using enzyme-linked immunosorbent assay (ELISA). Effects of different kinds of MSC were further evaluated in vitro by the coculture system.

Results: Results showed TLR4- and IFN-γ-activated MSC alleviated liver fibrosis in infected mice, without a significant increase of mortality, and unpretreated MSC showed no clear improvement; however, TLR2- and IFN-γ-activated MSC displayed aggravated immunopathology. In accord with the pathological results, TLR4- and IFN-γ-activated MSC groups showed moderate enhancement of Th1 response in vitro and clear Th1 dominance in vivo without leading to extreme inflammation, whereas TLR2- and IFN-γ-activated MSC not only induced Th1 response, but also triggered excessive inflammation as evidenced by atrophy of the thymus and higher TNF level in the coculture system.

Conclusions: This study demonstrates that TLR4 combined with IFN-γ can activate the MSC group with positive effects on the pathology of schistosomiasis by modulating Th subsets at some degree. This result suggests that when MSC is being used to treat different immuno-disturbance complications, subtle pretreatment methods should be seriously considered.

Citing Articles

Macrophage MST1 protects against schistosomiasis-induced liver fibrosis by promoting the PPARγ-CD36 pathway and suppressing NF-κB signaling.

Li J, Cai X, Yang Y, Mao Y, Ding L, Xue Q PLoS Pathog. 2024; 20(12):e1012790.

PMID: 39700261 PMC: 11785294. DOI: 10.1371/journal.ppat.1012790.


Pretreatment can alleviate programmed cell death in mesenchymal stem cells.

Wan X, Hu X, Zhang Q, Xiong K World J Stem Cells. 2024; 16(8):773-779.

PMID: 39219726 PMC: 11362856. DOI: 10.4252/wjsc.v16.i8.773.


Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management.

Zhang J, Wu P, Wen Q Stem Cell Res Ther. 2024; 15(1):211.

PMID: 39020426 PMC: 11256674. DOI: 10.1186/s13287-024-03828-8.


Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity.

Liu J, Wan X, Zheng S, Khan M, He H, Feng Y Curr Stem Cell Res Ther. 2023; 19(9):1175-1184.

PMID: 37817652 DOI: 10.2174/011574888X268740231002054459.


IgG persistence showed weak clinical aspects in chronic schistosomiasis patients.

Xie S, Zhang Y, Li J, Zhou J, Li J, Zhang P Sci Rep. 2023; 13(1):13222.

PMID: 37580417 PMC: 10425409. DOI: 10.1038/s41598-023-40082-z.


References
1.
Peng H, Zhang Q, Li X, Liu Z, Shen J, Sun R . IL-33 Contributes to Schistosoma japonicum-induced Hepatic Pathology through Induction of M2 Macrophages. Sci Rep. 2016; 6:29844. PMC: 4956744. DOI: 10.1038/srep29844. View

2.
Wilson M, Mentink-Kane M, Pesce J, Ramalingam T, Thompson R, Wynn T . Immunopathology of schistosomiasis. Immunol Cell Biol. 2006; 85(2):148-54. PMC: 3437548. DOI: 10.1038/sj.icb.7100014. View

3.
Wellhausen S, Boros D . Atrophy of the thymic cortex in mice with granulomatous schistosomiasis mansoni. Infect Immun. 1982; 35(3):1063-9. PMC: 351155. DOI: 10.1128/iai.35.3.1063-1069.1982. View

4.
Kim D, Lee W, Lee M, Park H, Jang I, Lee J . Involvement of TLR3-Dependent PGES Expression in Immunosuppression by Human Bone Marrow Mesenchymal Stem Cells. Stem Cell Rev Rep. 2017; 14(2):286-293. DOI: 10.1007/s12015-017-9793-6. View

5.
El-Shennawy S, Abdel Aaty H, Radwan N, Abdel-Hameed D, Alam-Eldin Y, El-Ashkar A . Therapeutic Potential of Mesenchymal Stem Cells on Early and Late Experimental Hepatic Schistosomiasis Model. J Parasitol. 2015; 101(5):587-97. DOI: 10.1645/15-754.1. View